Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill creates a Medicare Radiation Oncology Case Rate Value Based Payment Program (ROCR) that replaces fee‑for‑service payments for many radiation therapy episodes with per‑episode bundled payments, quality incentives, accreditation requirements, and a health‑equity add‑on for transportation insecurity.
It exempts savings from this program from certain Medicare budget‑neutrality adjustments, removes participating radiation therapy providers from MIPS, establishes documentation and reporting rules, limits inclusion of certain advanced modalities for up to 12 years, and creates a limited civil‑penalty exception permitting free or discounted non‑luxury transportation under specific safeguards.
Technocratic, industry-targeted reform has bipartisan appeal potential but significant fiscal/legal changes and complexity lower enactment odds absent strong stakeholder consensus and a funding score.
Relative to its intended legislative type, this bill is a detailed substantive statutory reform that creates a new Medicare value-based per-episode payment program for radiation oncology, integrates with existing Medicare law, and includes defined goals, many operational rules, and periodic evaluation requirements.
Liberals emphasize transportation equity and accreditation benefits.
Liberals emphasize transportation equity and accreditation benefits.
Likely cautiously supportive on balance.
The equity add‑on for transportation, accreditation standards, and emphasis on patient‑centered care align with access and quality goals.
However, concerns remain about the continued 20% coinsurance, the long exclusion period for certain advanced therapies, and whether payment limits could reduce access in underserved communities.
Generally supportive as a pragmatic payment reform that aims to stabilize prices, encourage efficiency, and protect access with accreditation and oversight.
The bill contains reasonable transition rules, GAO evaluation, and payment protections, but implementation details, cost impacts, and regulatory complexity merit careful rulemaking scrutiny.
Mixed to skeptical.
The program’s bundled payments and explicit aim to contain Medicare spending are attractive, as is removal from MIPS.
But the law expands federal regulation via accreditation, imposes participation rules, delays inclusion of new technologies for 12 years, and retains beneficiary coinsurance, raising concerns about federal overreach and unintended access consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technocratic, industry-targeted reform has bipartisan appeal potential but significant fiscal/legal changes and complexity lower enactment odds absent strong stakeholder consensus and a funding score.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize transportation equity and accreditation benefits.
Technocratic, industry-targeted reform has bipartisan appeal potential but significant fiscal/legal changes and complexity lower enactment…
Relative to its intended legislative type, this bill is a detailed substantive statutory reform that creates a new Medicare value-based per-episode payment program for radiation oncology, integrates with existing Medica…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.